Due to the rather limited growth effect obtained after stable transfection, antisense gene therapies exclusively against eIF-4A1 would be not sufficient in melanoma, however, they may be contributory and helpful in combination with other gene targets. The gene discussed is EIF4A1; the disease is melanoma.